PRE-EMPT studies examine prevention of adverse maternal, foetal and neonatal outcomes. There is a considerable literature devoted to the prevention of pre-eclampsia in order to avoid the associated maternal and perinatal complications. Although the strength of evidence around various interventions to prevent pre-eclampsia varies, at a population level, there is an inverse relationship between dietary calcium intake and both blood pressure among non-pregnant individuals and the incidence of pre-eclampsia.
Among fetuses, severe early-onset fetal growth restriction can lead to a range of adverse outcomes including fetal or neonatal death, neurodisability, and lifelong risks to the health of the affected child. Sildenafil, a phosphodiesterase type 5 inhibitor, potentiates the actions of nitric oxide, which leads to vasodilatation of the uterine vessels and might improve fetal growth in utero.
The questions tested in our studies are:
Can high-risk women who have low dietary intake of calcium (<600 mg/d) benefit from calcium supplementation (of at least 1 g/d, orally)- the Calcium and Pre-eclampsia (CAP) Trial: A WHO Collaboration
Can maternal treatment with oral sildenafil citrate improve perinatal outcomes in pregnancies complicated by severe early-onset IUGR without increasing risks to the mother? – The STRIDER Consortium